Infectious Disease Topics
RSSArticles
-
Elevated Procalcitonin Is Associated with Increased Mortality in Pulmonary Tuberculosis
A single-center, prospective, observational study found that an elevated procalcitonin level was associated with an increased risk of death in patients with pulmonary tuberculosis.
-
Duration of Viable SARS-CoV-2 Shedding in Immunocompromised COVID-19 Patients
Significantly immunocompromised patients with COVID-19 may shed cultivatable virus for as long as two months or more after symptom onset.
-
Treatment of COVID-19 Patients with Remdesivir, Hydroxychloroquine, Lopinavir, or Interferon Beta-1a
None of the four drugs studied was superior to placebo.
-
Casirivimab + Imdevimab Injection
Casirivimab/imdevimab should be used to treat mild to moderate COVID-19 in adults and patients ≥ 12 years of age weighing at least 40 kg who have tested positive for SARS-CoV-2.
-
Antibiotics for Traveler’s Diarrhea
International travel carries a risk of colonization by antimicrobial-resistant intestinal flora. Using quinolone, but not a macrolide, during travel further increases the risk of acquisition of extended-spectrum, beta-lactamase-producing Enterobacteriaceae.
-
Healthcare Personnel COVID-19 Hospitalizations and Vaccine Prioritization
During the period of study, 5.9% of individuals hospitalized for COVID-19-related reasons were healthcare providers (HCP), with approximately one-third involving HCP who were not expected to directly contact patients.
-
Even Moderate COVID-19 Cases Can Cause Serious Neurological Problems
Strokes, seizures, and movement disorders just a few complications observed.
-
Bamlanivimab Injection
Bamlanivimab is a neutralizing recombinant IgG1 monoclonal antibody that connects to the receptor-binding domain of the spike protein of SARS-CoV-2. The drug blocks attachment and entry of the virus into human cells.
-
Rifampin vs. Isoniazid for Latent Tuberculosis
A health system cost comparison showed that four months of rifampin was safer and less expensive than nine months of isoniazid in high-income countries, medium-income countries, and African countries.
-
FDA Issues Third COVID-19 Therapeutic EUA This Month
The list of COVID-19 therapeutics is growing rapidly.